Compositions and Methods for Increasing Drug Efficacy in Cancer

A pharmaceutical composition comprising:

• i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof;
• and
• ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof.

A kit comprising:

• i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof;
• ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof;
• and, iii) optionally, instructions for use of the kit in the treatment, prevention, slowing the progression or delaying the onset and/or development of a lymphoproliferative disease.

16-17. (canceled)

19-20. (canceled)

(canceled)

28-29. (canceled)

A method for increasing the efficacy of flavopiridol treatment in a subject having chronic lymphocytic leukemia (CLL), comprising:

• administering chloroquine or an autophagy-related gene (ATG) member antagonist to the subject in as an amount sufficient to reduce autophagy in the subject.

(canceled)

A method of modulating autophagy in a cell in need thereof, comprising potentiating at least one CDK inhibitor in the cell by administering to the cell an effective amount of at least one CDK inhibitor agent, a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof.

35-39. (canceled)

(canceled)

(canceled)

A method of reducing viability of a tumor cell in a subject, comprising:

• a) introducing into a tumor cell in the subject an agent effective to modulate endoplasmic reticulum (ER) stress response and sensitize the tumor cell to the therapeutic activity of an anticancer agent in the subject;
• and
• b) contacting the tumor cell with the anticancer agent in an amount effective to reduce viability of the sensitized tumor cell, wherein viability of the tumor cell is reduced.